Skip to content
Screener

Generate Biomedicines, Inc. GENB Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$6.3MBeat by $1.0M
EPS-$0.52Miss by $0.01
Revenue estimate$5.3M
EPS estimate-$0.51

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue$6.3M-37.7%
Operating income-$71.6M-19.1%
Net income-$67.3M-28.3%
EPS (diluted)-$0.52+73.2%

Balance sheet

See full
Cash & equivalents$135.4M-12.3%
Total debt$62.6M—
Total equity$456.0M+188%
Total assets$561.7M—

Cash flow

See full
Operating cash flow-$57.9M-18.9%
CapEx$933.0K+506%
Free cash flow-$58.9M-20.4%

Valuation & ratios

Valuation

as of 08/06/26
See full
Market cap$1.86B+19.8%
Enterprise value$1.78B—
P/S57.2×—

Returns & leverage

See full
Debt / equity0.1×—
Current ratio8.3×—

Versus estimates

Revenue

Q2 2026$6.3MBeat by $1.0M

Diluted EPS

Q2 2026-$0.52Miss by $0.01

FAQ

When did Generate Biomedicines, Inc. report Q2 2026 earnings?
Generate Biomedicines, Inc. (GENB) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Generate Biomedicines, Inc.'s Q2 2026 revenue and EPS?
Generate Biomedicines, Inc. reported revenue of $6.3M and eps of $-0.52 for Q2 2026.
Did Generate Biomedicines, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $5.3M by $1.0M. EPS missed the consensus estimate of $-0.51 by $0.01.
Where can I find Generate Biomedicines, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-336462) and the 10-Q periodic report (0001193125-26-336437) directly on SEC EDGAR. The filing index links above go to sec.gov.